Joseph G. Pressey · GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis
Follow
Article1 min read·Published Jan 2014Older

GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jan 2014 · 1 min read

In brief

In brief

This preclinical study demonstrates that GANT-61, a GLI1/2 inhibitor, reduces growth of both embryonal and alveolar rhabdomyosarcoma xenografts by approximately 50% through disruption of Shh/AKT-mTOR signaling and cell cycle arrest. The therapeutic effect is enhanced when combined with standard chemotherapy agents like temsirolimus or vincristine.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Rhabdomyosarcoma (RMS) typically arises from skeletal muscle. Currently, RMS in patients with recurrent and metastatic disease have no successful treatment. The molecular pathogenesis of RMS varies based on cancer sub-types. Some embryonal RMS but not other sub-types are driven by sonic hedgehog (Shh) signaling pathway. However, Shh pathway inhibitors particularly smoothened inhibitors are not highly effective in animals. Here, we show that Shh pathway effectors GLI1 and/or GLI2 are over-expressed in the majority of RMS cells and that GANT-61, a specific GLI1/2 inhibitor dampens the proliferation of both embryonal and alveolar RMS cells-derived xenograft tumors thereby blocking their growth. As compared to vehicle-treated control, about 50% tumor growth inhibition occurs in mice receiving GANT-61 treatment. The proliferation inhibition was associated with slowing of cell cycle progression which was mediated by the reduced expression of cyclins D1/2/3 & E and the concomitant induction of p21. GANT-61 not only reduced expression of GLI1/2 in these RMS but also significantly diminished AKT/mTOR signaling. The therapeutic action of GANT-61 was significantly augmented when combined with chemotherapeutic agents employed for RMS therapy such as temsirolimus or vincristine. Finally, reduced expression of proteins driving epithelial mesenchymal transition (EMT) characterized the residual tumors.

Statements in this article

  1. Rhabdomyosarcoma in patients with recurrent and metastatic disease have no successful treatment.

    Established
  2. Some embryonal rhabdomyosarcoma but not other sub-types are driven by sonic hedgehog signaling pathway.

    Established
  3. Smoothened inhibitors are not highly effective in animals for treating rhabdomyosarcoma.

    Research
  4. GLI1 and/or GLI2 are over-expressed in the majority of rhabdomyosarcoma cells.

    Research
  5. GANT-61 dampens the proliferation of both embryonal and alveolar rhabdomyosarcoma cells-derived xenograft tumors.

    Research
  6. About 50% tumor growth inhibition occurs in mice receiving GANT-61 treatment compared to vehicle-treated control.

    Research
  7. GANT-61 proliferation inhibition is associated with slowing of cell cycle progression mediated by reduced expression of cyclins D1/2/3 and E and concomitant induction of p21.

    Research
  8. GANT-61 reduces expression of GLI1/2 in rhabdomyosarcoma cells.

    Research
  9. GANT-61 significantly diminishes AKT/mTOR signaling in rhabdomyosarcoma.

    Research
  10. The therapeutic action of GANT-61 is significantly augmented when combined with temsirolimus or vincristine.

    Research
  11. Reduced expression of proteins driving epithelial mesenchymal transition characterizes residual tumors after GANT-61 treatment.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.